Induction of fibronectin by HER2 overexpression triggers adhesion and invasion of breast cancer cells

被引:37
|
作者
Jeon, Myeongjin [1 ,2 ]
Lee, Jeongmin [1 ]
Nam, S. J. [1 ]
Shin, Incheol [3 ]
Lee, J. E. [1 ,2 ]
Kim, Sangmin [1 ]
机构
[1] Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea
[2] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea
[3] Hanyang Univ, Dept Life Sci, Seoul 133791, South Korea
关键词
Fibronectin; HER2; Trastuzumab; Adhesion; Invasion; MESENCHYMAL TRANSITION; ADJUVANT CHEMOTHERAPY; EXPRESSION; TRASTUZUMAB; KINASE; GROWTH; EGF; ONCOGENE; THERAPY; PATHWAY;
D O I
10.1016/j.yexcr.2015.02.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Fibronectin (FN), an extracellular matrix ligand, plays a pivotal role in cell adhesion, migration, and oncogenic transformation. Aberrant FN expression is associated with poor prognoses in various types of cancer, including breast cancer. In the current study, we investigated the relationship between FN induction and HER2 expression in breast cancer cells. Our results showed that the level of FN expression increased in response to HER family ligands, EGF and TGF-alpha in a time- and dose-dependent manner. On the other hand, EGF-induced FN expression decreased in response to trastuzumab, which is a HER2-targeted monoclonal antibody. However, EGF-induced FN expression was not affected by trastuzumab in JIMT-1 breast cancer cells, which are trastuzumab insensitive cells. Next, we introduced the HER2 gene into MDA-MB231 cells to verify the relationship between FN and HER2. The level of FN expression significantly increased in HER2-overexpressed MDA-MB231 cells. In contrast, the induction of FN by HER2 was significantly decreased in response to trastuzumab treatment. In addition, the induction of FN by HER2 was down-regulated by the MEK 1/2 specific inhibitor, U0126. Using conditioned culture media of vec- and HER2-overexpressed MDA-MB231 cells, we observed the cell morphology, adhesion, and invasion of MDA-MB231 cells. Interestingly, in conditioned culture media of HER2-overexpressed MDA-MB231 cells, the cell morphology was altered, and adhesion and invasion of MDA-MB231 cells significantly increased. In addition, our results showed that recombinant human FN augmented cell adhesion and invasion of MDA-MB231 cells while these inductions decreased in response to an FN inhibitor. Therefore, we demonstrated that the induction of FN by HER2 triggers cell adhesion and invasion capacities. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:116 / 126
页数:11
相关论文
共 50 条
  • [31] HER2 Testing in Gastric Cancer
    Albarello, Luca
    Pecciarini, Lorenza
    Doglioni, Claudio
    ADVANCES IN ANATOMIC PATHOLOGY, 2011, 18 (01) : 53 - 59
  • [32] Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
    Tantiwetrueangdet, Anchalee
    Panvichian, Ravat
    Wongwaisayawan, Sansanee
    Sueangoen, Natthaporn
    Lertsithichai, Panuwat
    MEDICAL ONCOLOGY, 2018, 35 (12)
  • [33] Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells
    Paris, Luisa
    Cecchetti, Serena
    Spadaro, Francesca
    Abalsamo, Laura
    Lugini, Luana
    Pisanu, Maria Elena
    Iorio, Egidio
    Natali, Pier Giorgio
    Ramoni, Carlo
    Podo, Franca
    BREAST CANCER RESEARCH, 2010, 12 (03)
  • [34] A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells
    Papadakis, Emmanouil
    Robson, Natalia
    Yeomans, Alison
    Bailey, Sarah
    Laversin, Stephanie
    Beers, Stephen
    Sayan, A.
    Ashton-Key, Margaret
    Schwaiger, Stefan
    Stuppner, Hermann
    Troppmair, Jakob
    Packham, Graham
    Cutress, Ramsey
    ONCOTARGET, 2016, 7 (14) : 18851 - 18864
  • [35] Impact of the 2018 ASCO/CAP HER2 guidelines update for HER2 testing by FISH in breast cancer
    Xu, Bin
    Shen, Jianguo
    Guo, Wenhao
    Zhao, Wenhe
    Zhuang, Yiyu
    Wang, Linbo
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (02) : 251 - 255
  • [36] A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression
    Nathalie Reix
    Charlotte Malina
    Marie-Pierre Chenard
    Jean-Pierre Bellocq
    Stéphanie Delpous
    Sébastien Molière
    Anthony Sevrin
    Karl Neuberger
    Catherine Tomasetto
    Carole Mathelin
    Breast Cancer Research and Treatment, 2016, 160 : 249 - 259
  • [37] Tracking and Evaluating Molecular Tumor Markers With Cancer Registry Data: HER2 and Breast Cancer
    Anderson, William F.
    Rosenberg, Philip S.
    Katki, Hormuzd A.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (05):
  • [38] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [39] Simultaneous measurement of ERα, HER2, and PhosphoERK1/2 in breast cancer cell lines by flow cytometry
    Bayraktar, Ulas Darda
    Kim, Tae Kon
    Drews-Elger, Katherine
    Benjamin, Cara
    El-Ashry, Dorraya
    Wieder, Eric
    Komanduri, Krishna V.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (02) : 623 - 628
  • [40] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676